Prof Dr. Birgit Schilling | X-linked dystonia-parkinsonism (XDP) and Proteomics | Best Researcher Award
Buck Institute for Research on Aging | United States
EARLY ACADEMIC PURSUITS:
With a career spanning over two decades, you began your academic journey with a focus on protein chemistry and mass spectrometric technologies. These early academic pursuits laid the foundation for your expertise in proteomics, specifically within the context of aging research.
Your professional endeavors have been diverse and impactful. As the Director of the Mass Spectrometry Center at the Buck Institute for Research on Aging, you have played a pivotal role in advancing research projects across various domains, from neurodegenerative diseases to cancer, diabetes, mitochondrial damage, and bacterial pathogenesis. Your involvement in national U01 consortiums and U54 Tissue Mapping Center reflects your commitment to collaborative, cutting-edge research.
CONTRIBUTIONS AND RESEARCH FOCUS ON X-LINKED DYSTONIA-PARKINSONISM (XDP) AND PROTEOMICS:
Your contributions to the field of proteomics are noteworthy, particularly in the molecular mechanisms of aging and protein posttranslational modifications. Your engagement in a P01 program project grant and the Senescence Network SenNet initiative underscores your dedication to understanding senescence and its implications. The investigation of the senescence-associated secretory phenotype (SASP) in neurodegeneration highlights your pursuit of unraveling critical aspects of aging-related processes.
IMPACT AND INFLUENCE:
Collaborations with esteemed researchers, including Drs. Ellerby and Campisi, showcase the impact and influence you've had in your field. Your multi-PI roles, leadership in a 'Senescence Core,' and participation in a P30 Nathan Shock Center award underscore your leadership and influence in shaping research agendas and collaborative efforts.
Your extensive collaborations and publications, spanning over 20 years with Drs. Ellerby and Campisi, contribute significantly to the academic literature. The depth and breadth of your work have likely resulted in numerous citations, reflecting the scholarly impact of your research within the scientific community.
As a leader in proteomics and aging research, your legacy is marked by a prolific body of work and collaborative initiatives. Your role in technology development awards and organ-on-a-chip systems further cements your legacy as a forward-thinking scientist driving innovation in the field.
Looking ahead, your involvement in ongoing studies for Huntington's and Alzheimer's disease, as well as your exploration of the SASP in neurodegeneration, positions you for continued influential contributions. Your leadership in various consortia and core facilities suggests a future marked by continued advancements at the intersection of mass spectrometry, proteomics, and aging research.